Quoin Pharmaceuticals, Ltd.
QNRXReported to SECin USCIK 0001671502Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 6. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Carter Denise P.Chief Operating Officer | Open-market buy | $99,99120,490 shares | Sep 1, 2026 | Carter Denise P.Chief Operating Officer | $99,991 | Open-market buy | 20,490 | Sep 1, 2026 |
| Myers MichaelChief Executive Officer | Open-market buy | $99,99120,490 shares | Sep 1, 2026 | Myers MichaelChief Executive Officer | $99,991 | Open-market buy | 20,490 | Sep 1, 2026 |
| Lawlor Sally BridgetChief Financial Officer | Open-market buy | $49,99110,244 shares | Sep 1, 2026 | Lawlor Sally BridgetChief Financial Officer | $49,991 | Open-market buy | 10,244 | Sep 1, 2026 |
| Culverwell Anthony James— | Open-market buy | $29,9926,146 shares | Sep 1, 2026 | Culverwell Anthony James | $29,992 | Open-market buy | 6,146 | Sep 1, 2026 |
| LANGER DENNIS— | Award | $177,85034,534 shares | Aug 28, 2026 | LANGER DENNIS | $177,850 | Award | 34,534 | Aug 28, 2026 |
Lobbying
From the quarterly LD-2 filings at the U.S. Senate — a different register, and a different kind of fact.
This is not a trade and it is not scored. A lobbying filing says who lobbied for whom, on which issues, and for how much — it says nothing about the share price and nothing about this company’s insiders. The link between the client names in that register and Quoin Pharmaceuticals, Ltd. is a reviewed rule of ours: an LD-2 names a client and carries no ticker, no CIK and no LEI.